[
  {
    "info": {
      "NCT": "NCT04827576",
      "Protocol_No": "GS-US-548-5918",
      "jit": "Optimal",
      "trial_name": "Gilead GS-US-548-5918"
    },
    "disease": {
      "summary": "locally advanced or metastatic mNSCLC and mSCLC metastatic urothelial cancer ",
      "details": [
        {
          "code": "Bladder/Urinary Tract (BLADDER)",
          "selection": "include",
          "stage": "Advanced Stage;Metastatic"
        },
        {
          "code": "Combined Small Cell Lung Carcinoma (CSCLC)",
          "selection": "include",
          "stage": "Advanced Stage;Metastatic"
        },
        {
          "code": "Non-Small Cell Lung Cancer (NSCLC)",
          "selection": "include",
          "stage": "Advanced Stage;Metastatic"
        }
      ]
    },
    "query": {
      "nct": "NCT04827576",
      "title": "Study of Magrolimab in Participants With Solid Tumors",
      "current_status": "Recruiting",
      "status_verif_date": "July 2022",
      "last_update_date": "August 24, 2022",
      "trial_hold_status": "open",
      "sponsor": "Gilead Sciences",
      "brief_summary": "The primary objectives of the study are to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors (Safety Run-in Cohort 1, Phase 2 Cohorts 1a,\n\n1b, and 1c) and to evaluate the efficacy of magrolimab + docetaxel combination therapy in solid tumors as determined by investigator-assessed objective response rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)",
      "conditions": "Solid Tumor",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Safety Run-in Cohort 1, mNSCLC, mUC, mSCLC (Magrolimab + Docetaxel)",
          "drug": "Magrolimab | Docetaxel",
          "arm_type": "Experimental",
          "line_of_therapy": "1;2;3",
          "arm_hold_status": "Not available",
          "biomarker": [
            {
              "cohort": "Safety Run-in Cohort 1, mNSCLC, mUC, mSCLC (Magrolimab + Docetaxel)",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)",
          "drug": "Magrolimab | Docetaxel",
          "arm_type": "Experimental",
          "line_of_therapy": "1;2",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)",
          "drug": "Magrolimab | Docetaxel",
          "arm_type": "Experimental",
          "line_of_therapy": "2;3",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        },
        {
          "ArmID": "4",
          "cohortlabel": "Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)",
          "drug": "Magrolimab | Docetaxel",
          "arm_type": "Experimental",
          "line_of_therapy": "1;2",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "Not available",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "absent"
            }
          ]
        }
      ],
      "docs": "<a href=\"https://www.optimalresearchportal.com/login/\" target=\"_blank\">Optimal<\/a>",
      "locations": "Sioux Falls SD",
      "doclastupdate": "2023-01-20",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT04827576\" target=\"_blank\">NCT04827576<\/a>"
    }
  }
]
